Argenx
Willemstraat 5
Breda
4811 AH
Tel: 31-0-10-763-030-488
Website: http://www.argenx.com/
Email: nfo@argenx.com
About Argenx
argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.YEAR FOUNDED:
2008
LEADERSHIP:
CEO: Tim Van Hauwermeiren
CFO: Eric Castaldi
CSO: Hans de Haard
CDO: Torsten Dreier
CMO: Nicolas Leupin
JOBS:
Please click here for Argenx job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
125 articles with Argenx
-
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
8/11/2022
argenx (Euronext & Nasdaq: ARGX), today announced that the European Commission (EC) has granted marketing authorization for VYVGART™ (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
-
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
7/28/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its half year 2022 financial results and provided a second quarter business update.
-
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
7/28/2022
argenx SE announced that an extraordinary general meeting of shareholders will be held at 18:30 PM CEST on Thursday, September 8, 2022 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.
-
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
7/21/2022
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that it will host a conference call and audio webcast on Thursday, July 28, 2022 at 2:30 pm CET to discuss its half year 2022 financial results and provide a second quarter business update.
-
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
6/24/2022
argenx announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended European Commission approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.
-
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel
6/6/2022
Medison Pharma announced today an exclusive multi-regional agreement with argenx to commercialize efgartigimod in 14 countries.
-
argenx to Present at Upcoming Investor Conferences - June 01, 2022
6/1/2022
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that members of management will participate in several upcoming investor conferences in June:
-
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
5/31/2022
argenx SE announced that efgartigimod, the Company’s neonatal Fc receptor blocker has been awarded a positive scientific opinion by the MHRA under the EAMS.
-
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
5/19/2022
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the publication of novel translational data from the open-label Phase 2 study of efgartigimod for the treatment of pemphigus that further support the potential role of FcRn blockade and potential of efgartigimod in autoimmune skin blistering disorders.
-
argenx announces results of Annual General Meeting of Shareholders
5/10/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that all proposed resolutions at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed.
-
Two biologic therapeutic candidates have met their primary endpoints in phase III trials, including AstraZeneca’s Champion-NMOSD trial and Argenx’s Advance trial.
-
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported financial results for the first quarter 2022 and provided a business update.
-
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
5/5/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced positive data from the Phase 3 ADVANCE trial of VYVGART® in adults with primary ITP.
-
argenx to Present at BofA Securities 2022 Healthcare Conference
5/4/2022
argenx announced that members of management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 10:40 a.m. P.T. in Las Vegas, NV.
-
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
4/28/2022
argenx announced that it will host a conference call and audio webcast on Thursday, May 5, 2022 at 2:30 pm CET to discuss its first quarter 2022 financial results and provide a business update.
-
Discover what's in store for today's presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
-
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
4/5/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced interim results from ADAPT+, an ongoing Phase 3, open-label, three-year extension study evaluating long-term safety, tolerability and efficacy of VYVGART® for the treatment of adults with gMG.
-
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
4/1/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that interim data will be presented from ADAPT+ at the American Academy of Neurology Annual Meeting in Seattle, WA, April 2-7.
-
argenx announces full exercise of underwriters’ option to purchase additional ADSs
3/29/2022
argenx SE announced that the underwriters of its previously announced global offering of ordinary shares have exercised in full their option to purchase 350,000 additional ordinary shares in the form of ADSs on the same terms and conditions as the global offering.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.